NASDAQ · HTFL
Healthcare · Medical - Healthcare Information Services
$59.05
Down-$1.48 (-2.45%)
Updated Nov 2, 2026, 2:29 AM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HTFL
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
HTFL closed at $59.05 after 20 trading sessions, up 13.10% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $59.00 | $59.545 | $56.93 | $59.05 | 2.25M |
| Oct 29, 2026 | $59.00 | $60.56 | $58.50 | $60.53 | 1.3M |
| Oct 28, 2026 | $58.06 | $60.29 | $56.42 | $59.10 | 1.64M |
| Oct 27, 2026 | $56.95 | $59.90 | $55.99 | $57.82 | 1.79M |
| Oct 26, 2026 | $57.31 | $57.55 | $56.32 | $57.005 | 1.06M |
| Oct 23, 2026 | $55.27 | $57.74 | $54.6047 | $56.71 | 1.56M |
| Oct 22, 2026 | $55.01 | $56.7199 | $54.45 | $55.43 | 1.3M |
| Oct 21, 2026 | $55.60 | $57.25 | $55.33 | $55.82 | 1.58M |
| Oct 20, 2026 | $51.92 | $56.295 | $51.00 | $55.59 | 3.03M |
| Oct 19, 2026 | $48.70 | $51.78 | $48.70 | $51.02 | 1.6M |
| Oct 16, 2026 | $50.64 | $50.99 | $47.97 | $48.29 | 1.02M |
| Oct 15, 2026 | $48.37 | $51.8425 | $47.39 | $50.905 | 1.5M |
| Oct 14, 2026 | $49.46 | $50.87 | $48.85 | $49.46 | 1.62M |
| Oct 13, 2026 | $50.84 | $51.57 | $49.91 | $50.32 | 1.5M |
| Oct 12, 2026 | $49.75 | $51.69 | $49.1801 | $50.56 | 1.42M |
| Oct 9, 2026 | $47.64 | $50.00 | $47.26 | $49.74 | 812.89K |
| Oct 8, 2026 | $48.54 | $49.66 | $46.50 | $47.63 | 1.99M |
| Oct 7, 2026 | $49.76 | $51.50 | $48.44 | $49.36 | 1.44M |
| Oct 6, 2026 | $54.00 | $54.3195 | $49.51 | $50.69 | 2.91M |
| Oct 5, 2026 | $49.29 | $53.07 | $49.29 | $52.21 | 2.45M |
The latest Smart Investors Daily articles mentioning HTFL.
Company
Market Activity
Research & News
HTFL research
Company profile and research snapshot.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | Piper Sandler | Overweight | — |
| Sep 22, 2026 | Canaccord Genuity | Buy | — |
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 14, 2026 | Wells Fargo | Overweight | — |
| Aug 14, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
BOSTON, October 23, 2026--Elucid Bioimaging Inc. ("Elucid") today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products.
Benzinga · Oct 23, 2026
Elucid Bioimaging Inc. ("Elucid") today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology
Benzinga · Oct 23, 2026
https://news.bloomberglaw.com/ip-law/heartflow-says-elucid-stole-trade-secrets-infringed-patents
Benzinga · Oct 20, 2026
Piper Sandler analyst Matt OBrien reiterates HeartFlow (NASDAQ:HTFL) with a Overweight and raises the price target from $45 to $64.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HTFL.
